FGF-21 Elevated IL-10 Production to Correct LPS-Induced Inflammation

  • Inflammation. 2018 Jun;41(3):751-759. doi: 10.1007/s10753-018-0729-3.
Jun-Yan Li  1 ,  Nan Wang  1 ,  Mir Hassan Khoso  1 ,  Cheng-Bin Shen  1 ,  Meng-Ze Guo  1 ,  Xin-Xin Pang  1 ,  De-Shan Li  2 ,  Wen-Fei Wang  3
Affiliations
  • 1. Northeast Agricultural University, School of Life Science, Harbin, Heilongjiang Province, China.
  • 2. Northeast Agricultural University, School of Life Science, Harbin, Heilongjiang Province, China. [email protected].
  • 3. Life Science and Biotechnique Research Center, A Division of Northeast Agricultural University, Harbin, Heilongjiang Province, 150030, China. [email protected].
PMID: 29427162 DOI: 10.1007/s10753-018-0729-3
Abstract

Fibroblast Growth Factor 21 (FGF-21) has been previously judged as a major metabolic regulator. In this paper, we show that FGF-21 has a potential role in anti-inflammation and immunoregulation. In vivo, treatment with exogenous FGF-21 can alleviate LPS-induced inflammation. In vitro, FGF-21 inhibited LPS-induced IL-1β expression in THP-1 cells. Furthermore, besides the NF-κB pathway, the mechanism of action of FGF-21 was observed to involve the elevation of IL-10 in the ERK1/2 pathway. This study clearly indicates that FGF21 can be used as an attractive target for the management of inflammatory disorders. This piece of research indicates that FGF-21 could have much value in the management of inflammatory disorders.

Keywords
FGF-21; IL-10; LPS; THP-1 cells.
Products